Abstract: The present invention provides a drug for a pathological condition including mitochondria-related disease by a conjugate of a double-membrane organelle DNA sequence recognizing compound and a double-membrane organelle localizable compound. The present invention provides a conjugate in which a double-membrane organelle localizable lipophilic cation is attached to linear PI polyamide that specifically binds to a double-membrane organelle DNA sequence, a linear PI polyamide-TPP conjugate targeting the mitochondrial DNA mutation or polymorphism, comprising the conjugate, and a pharmaceutical composition comprising the conjugate.

Abstract: The present invention provides a novel alkylating agent specifically binding to the genetic mutation site of a driver oncogene. There are provided are a complex formed by binding an alkylating agent to a pyrrole imidazole polyamide specifically binding to the genetic mutation site of a driver oncogene, a driver oncogene mutation-specific alkylating agent comprising the aforementioned complex, and a pharmaceutical composition comprising the aforementioned complex.

Abstract: The present invention provides a novel alkylating agent specifically binding to the genetic mutation site of a driver oncogene. There are provided are a complex formed by binding an alkylating agent to a pyrrole imidazole polyamide specifically binding to the genetic mutation site of a driver oncogene, a driver oncogene mutation-specific alkylating agent comprising the aforementioned complex, and a pharmaceutical composition comprising the aforementioned complex.

Abstract: The present invention provides a novel alkylating agent specifically binding to the genetic mutation site of a driver oncogene. There are provided are a complex formed by binding an alkylating agent to a pyrrole imidazole polyamide specifically binding to the genetic mutation site of a driver oncogene, a driver oncogene mutation-specific alkylating agent comprising the aforementioned complex, and a pharmaceutical composition comprising the aforementioned complex.

Abstract: The present invention provides a novel alkylating agent specifically binding to the genetic mutation site of a driver oncogene. There are provided are a complex formed by binding an alkylating agent to a pyrrole imidazole polyamide specifically binding to the genetic mutation site of a driver oncogene, a driver oncogene mutation-specific alkylating agent comprising the aforementioned complex, and a pharmaceutical composition comprising the aforementioned complex.

Abstract: An object of the present invention is to provide a novel alkylating agent that specifically binds to an immune checkpoint gene to induce cell death, and has tumor-specific accumulating properties. The present invention provides a conjugate comprising an alkylating agent bonded to a polyamide that specifically binds to a gene encoding an immune checkpoint molecule, an alkylating agent specific for a gene encoding an immune checkpoint molecule, comprising the conjugate, and a pharmaceutical composition comprising the conjugate.

Abstract: The present invention provides a novel alkylating agent specifically binding to the genetic mutation site of a driver oncogene. There are provided are a complex formed by binding an alkylating agent to a pyrrole imidazole polyamide specifically binding to the genetic mutation site of a driver oncogene, a driver oncogene mutation-specific alkylating agent comprising the aforementioned complex, and a pharmaceutical composition comprising the aforementioned complex.

Abstract: Novel means that enables prediction of prognosis of a patient with cancer or inflammatory disease is disclosed. In the method for prediction of prognosis of a patient with cancer or inflammatory disease according to the present invention, the expression level of the FROUNT gene in a sample collected from the patient is measured. Since FROUNT is a poor prognostic factor, the lower the expression level of the FROUNT gene is, the better the prognosis in the patient is predicted to be. Or, the expression level of the CC chemokine receptor/ligand gene in a sample collected from the patient is measured. Since the CC chemokine receptor/ligand gene such as CCR2 or CCR5 is a good prognostic factor, the higher the expression level of the CC chemokine receptor/ligand gene is, the better the prognosis in the patient is predicted to be.

Abstract: The present invention provides a novel alkylating agent specifically binding to the genetic mutation site of a driver oncogene. There are provided are a complex formed by binding an alkylating agent to a pyrrole imidazole polyamide specifically binding to the genetic mutation site of a driver oncogene, a driver oncogene mutation-specific alkylating agent comprising the aforementioned complex, and a pharmaceutical composition comprising the aforementioned complex.

Abstract: A novel cancer marker is provided. A method for detecting cancer using a level of BMCC1 gene expression as an indication is provided, in which the cancer is selected from the group consisting of prostate cancer, lung cancer, gastric cancer, bladder cancer, and uterine cancer.

Abstract: Screening methods for determining pro-apoptotic compounds or anti-apoptotic compounds comprise measuring the interaction between p53 and NEDL1 in the presence and in the absence of a test compound, and comparing the strength of interaction between p53 and NEDL1 in the presence and in the absence of the test compound.

Abstract: Screening methods for determining pro-apoptotic compounds or anti-apoptotic compounds comprise measuring the interaction between p53 and NEDL1 in the presence and in the absence of a test compound, and comparing the strength of interaction between p53 and NEDL1 in the presence and in the absence of the test compound.

Abstract: A novel cancer marker is provided. A method for detecting cancer using a level of BMCC1 gene expression as an indication is provided, in which the cancer is selected from the group consisting of prostate cancer, lung cancer, gastric cancer, bladder cancer, and uterine cancer.

Abstract: The objective of the present invention is to provide methods of screening therapeutic agents for juvenile familial amyotrophic lateral sclerosis (ALS2). The invention provides a method of screening therapeutic agents for juvenile familial amyotrophic lateral sclerosis, comprising a step of assessing a substance that suppresses the expression of Tollip in cells as a therapeutic agent for juvenile familial amyotrophic lateral sclerosis; a method of screening therapeutic agents for juvenile familial amyotrophic lateral sclerosis, comprising a step of assessing a substance that promotes migration of Tollip in cells from the cytoplasm to the cell nucleus as a therapeutic agent for juvenile familial amyotrophic lateral sclerosis; and a method of screening therapeutic agents for juvenile familial amyotrophic lateral sclerosis, comprising a step of assessing a substance that inhibits the interaction between Tollip and IRAK-1 in cells as a therapeutic agent for juvenile familial amyotrophic lateral sclerosis.

Abstract: A method for screening a pro-apoptotic compound comprising a determination step of determining a compound enhancing interaction between p73 and IKK-? as a pro-apoptotic compound.

Abstract: A screening method comprising the following steps is provided. A step of culturing cells in the presence and in the absence of a test compound, a step of measuring HIF-1? expression in the respective cultured cells, and a step of determining the test compound to be a compound that inhibits onset or progression of familial amyotrophic lateral sclerosis if the HIF-1? expression in the cells cultured in the presence of the test compound is less than the HIF-1? expression in the cells cultured in the absence of the test compound.

Abstract: A microarray for predicting the prognosis of neuroblastoma, wherein the microarray has 25 to 45 probes related to good prognosis, which are hybridized to a gene transcript whose expression is increased in a good prognosis patient with neuroblastoma and are selected from 96 polynucleotides consisting of the nucleotide sequences of SEQ. ID NOs. 1, 5, 6, 14. 16, 17, 19, 22-24, 28, 29, 31, 37, 39, 40, 43, 44, 47-52, 54, 57-60, 62, 64, 65, 67, 68, 72-75, 77, 78, 80-82, 84, 87, 89-91, 94, 100, 103, 112, 113, 118, 120, 129, 130, 132, 136, 138, 142, 144, 145, 148, 150-153, 155, 158-160, 163-165, 169-171, 173, 174, 177, 178, 180-182, 184, 186, 187, 189, 191, 192, 194, 195, 198-200 or their partial continuous sequences or their complementary strands, and 25 to 45 probes related to poor prognosis, which are hybridized to a gene transcript whose expression is increased in a poor prognosis patient with neuroblastoma and are selected from 104 polynucleotides consisting of the nucleotide sequences of SEQ. ID NOs.

Abstract: Diagnostic agent or kit for the prognosis of neuroblastoma is used to diagnose the prognosis of neuroblastoma (particularly, classifying its progress and determining stage 4s neuroblastoma), which agent or kit comprising a nucleic acid probe, nucleic acid primers, or a nucleic acid microarray utilizing a nucleic acid comprising one sequence selected from the group consisting of nucleic acids set forth in SEQ ID NO:1 to SEQ ID NO:174, a fragment thereof, or a combination of either or both.

Abstract: There are disclosed a nucleic acid which is derived from the gene expressed in human neuroblastoma, and which comprises any sequence selected from the group consisting of the nucleic acid sequences set forth SEQ ID NO:1 to NO:104 in the Sequence Listing, or its complementary nucleic acid; a fragment of the nucleic acid; their use as probes or primers; and the diagnosis of neuroblastoma prognosis using any of the foregoings.

Abstract: A nucleic acid comprising any one of base sequences set forth in SEQ ID NO:1 to NO:104 in the Sequence Listing and a protein encoded by the nucleic acid, particularly a nucleic acid displaying differential expression levels in hepatoblastoma and normal liver based on comparison therebetween and a protein encoded by the nucleic acid as well as tumor detection utilizing the foregoing.